VIVO Meridian Bioscience Inc.

Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers

CINCINNATI, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix. This specialized master mix offers a cost-effective and easier alternative to freeze-drying for ambient temperature stable real-time PCR assays.

Meridian’s Air-Dryable qPCR Mix has been designed to simplify assay development and workflow through a magnesium containing formulation allowing air or oven drying protocols. Incorporation of the Air-Dryable qPCR mix in MDx assays allows dry down and test stability at ambient temperature, removing the need for cold chain shipping and storage. The Meridian Air-Dryable qPCR Mix shows exceptionally high performance in multiplex reactions following rehydration, making it ideally suited for automated high-throughput platforms.

Molecular diagnostic tests are progressively moving towards a dried down format; however, there are technical challenges in developing lyophilization-compatible mixes that require expensive lyophilization equipment. Building on its expertise in ready-to-use, lyophilization-compatible products, the Life Science division of Meridian Bioscience has successfully developed a ready-to-use, air-dryable mix to suit a growing demand within the molecular diagnostics industry for less complicated and cost-effective method of drying their assays.

Lourdes Weltzien, PhD, Executive Vice President, commented, “We are proud to announce the release of our new Air-Dryable qPCR Mix. We now have an alternative to our Lyo-Ready qPCR products that is ideal for our IVD and industry customers looking to increase operational efficiencies while reducing their overall costs. We remain committed to bringing innovation and quality products to molecular assay development.”

Florent Chang-Pi-Hin, PhD, Senior Director of Research and Development added, “We have seen a significant increase in demand for our Lyo-Ready mixes, however not all our customers have the expertise in house to do lyophilization. Following increasing customer demands, we have developed the Air-Dryable qPCR Mix as an easier and economic alternative that still provides the high accuracy expected of our qPCR products. The incorporation of magnesium in this optimized formulation is a great achievement and will enable our customers to simplify and speed up their assay development and workflow.”

For complete information, please visit meridianlifescience.com/molecular-dx-reagents.

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is

Meridian Contact:

Charlie Wood

Vice President – Investor Relations

Meridian Bioscience, Inc.

Phone:  +1 513.271.3700

Email:

EN
26/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Meridian Bioscience Inc.

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Stool Samples CINCINNATI, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the addition of two new Air-Dryable™ Master Mixes with the launch of its Air-Dryable™ Direct DNA qPCR Stool and Air-Dryable™ Direct RNA/DNA qPCR Stool Mixes. These innovative master mixes are designed to develop room-temperature stable molecular diagnostic assays that directly target nucleic acid sequences...

 PRESS RELEASE

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detec...

Meridian Launches Two New Air-Dryable qPCR Mixes Enabling Direct Detection of DNA or RNA from Saliva Samples CINCINNATI, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Saliva and Air-Dryable™ Direct RNA/DNA qPCR Saliva Mixes, which are designed for incorporation in room-temperature stable molecular assays, directly targeting nucleic acid sequence from saliva and sputum. Saliva is a complex fluid containing various enzy...

 PRESS RELEASE

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results

Meridian Bioscience Reports Third Quarter Fiscal 2021 Results CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submi...

 PRESS RELEASE

Meridian Closes Acquisition of BreathTek® Business

Meridian Closes Acquisition of BreathTek® Business CINCINNATI, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it closed the previously announced acquisition of the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. effective July 31, 2021. Information on the financial impacts to Meridian’s fiscal fourth quarter will be discussed on the quarterly earnings call scheduled for Friday, August 6, 2021. About Meridian Bioscience, Inc.Meridian is ...

 PRESS RELEASE

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H....

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc. CINCINNATI, July 23, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it signed a definitive agreement to acquire the North American BreathTek® business from Otsuka America Pharmaceutical, Inc. for $20 million in cash. The transaction is expected to close in Meridian’s fiscal fourth quarter. With this acquisition, Meridian will assume the customer relationshi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch